PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Encore Medical Asset Corporation

USPTO PatentsView assignee record - 9 granted patents across 1 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Encore ranks #28,673 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 1 technology areas.

#28,673
of 49,997 US assignees by volume
43rd percentile
by Innovation Score (33.0/100)
24.7
avg claims per patent
-87%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R28673 · US Corporation #28,673 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 9 grants
  • MID-PACK #28,673/49,997
  • PHOTO-FINISH Emery Oleochemicals
  • CPC-NARROW A61N · 1 areas
  • INNOV-THIN 33.0/100
  • CLAIMS-DENSE 24.7 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -87% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Emery Oleochemicals GmbH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Encore’s 33.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Encore

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Encore's Innovation Score is 33.0/100 (43rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Encore?

Each dot is one of Encore’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Encore’s own 24.7 claims/patent is ABOVE the 15.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Encore vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 8.98.999.1 51015202530 Granted patents (volume) Avg claims / patent Emery Oleochemicals GmbH - 9, 16.67Emery Oleochemica…Empow Cyber Security Ltd. - 9, 27.22Empow Cyber Secur…EnE Holdings Ltd - 9, 8.33Ene HoldingsEncompass Vascular, Inc. - 9, 26Encompass VascularEndovision Foundation - 9, 10Endovision Founda…Endura SPA - 9, 15Endura SPAEnevo Oy - 9, 16.89Enevo OyEnsitech IP Pty. Limited - 9, 8.11Ensitech IP PtyEncore Medical Asset Corporation - 9, 24.67Encore Medical As…
Encore vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Encore's grants concentrate

Encore Medical Asset Corporation is a focused PatentsView assignee: 1 CPC subclasses with 100% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2017 (3 grants) versus a trough of 1 in 2019. By volume, Encore sits between Emery Oleochemicals GmbH and Ensitech IP Pty. Limited.

Encore's three-year grant acceleration

Encore Medical Asset Corporation shows 1 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Encore's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Encore holds 9 patents at rank #28,697, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Encore

By rank, the assignees closest to #28,697 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Encore's primary technology class.

Encore's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 43rd percentile higher than 43% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 20152016201720192023 1
USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Encore Medical Asset Corporation patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 2 22.2%
2016 2 22.2%
2017 3 33.3%
2019 1 11.1%
2023 1 11.1%

Which technologies does Encore Medical Asset Corporation patent most?

Top 1 of 1 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Encore Medical Asset Corporation's patent record in context - here's where to go next.

  • Encore Medical Asset Corporation's lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 100% of its portfolio - see every assignee active in that class. Explore A61N
  • Ranked #28,673 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Encore Medical Asset Corporation against Emery Oleochemicals GmbH, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 33.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.